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ABSTRACT
Objective: Serum vitamin D is shown to be decreased and associated with higher thyroid volumes in Graves disease (GD). We aimed to 
investigate the relationship between thyroid volume and baseline serum vitamin D status in newly diagnosed GD patients.
Methods: This was a single-center cross-sectional study with a total of  61 new-onset GD patients (n=61, F: 40, M: 21) who were 
divided into two groups, according to baseline serum vitamin D levels, as Group-1 (vitamin D <20; n: 42) and  Group-2 (vitamin D 
≥20; n=19). Thyroid volume (mL) and isthmus measurements (mm) were compared between the two groups. 
Results: There was an inverse correlation between the baseline serum vitamin D levels and thyroid volume, thyroid receptor au-
toantibodies (TRAb), free triiodothyronine (fT3), and parathyroid hormone (PTH) levels (p=0.02, r=-0.31; p=0.005, r=-0.36; p=0.04, 
r=-0.26; p=0.02, r=-0.32, respectively). Thyroid volume was also correlated with serum free thyroxine (fT4), fT3, TRAb, and thyroid 
peroxidase autoantibodies (TPOAb; p=0.001, r=0.426; p=0.001, r=0.50; p=0.04, r=0.26; p=0.001, r=0.42, respectively). Low vitamin 
D and high thyroglobulin antibody (TgAb) levels were significantly associated with thyroid volume based on a regression analysis 
(p=0.03, odds ratio [OR]:18.7, 95% confidence interval [CI]: 1.34-260.91 and p=0.04, OR: 16.6, 95% CI: 1.07-255.64, respectively). 
Conclusion: Baseline serum vitamin D levels are inversely related with thyroid volumes, fT3, and TRAb levels  in new-onset GD. 
In addition to several advantages, optimization of vitamin D levels would also be beneficial in the surveillance of these patients. 
However, larger scale studies are required to make further suggestions.
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INTRODUCTION
Vitamin D is as a pro-hormone in the regulation of calcium and 
phosphate levels, and therefore it is particularly essential for 
bone and mineral metabolism. However, in recent years, many 
studies have been demonstrating an effect of vitamin D deficien-
cy in several diseases, such as cancer, hypertension, cardiovascu-
lar diseases, and diabetes mellitus as well as autoimmune thy-
roid disorders (1). Although vitamin D levels of over 20 ng/mL are 
considered sufficient for its skeletal effects, values over 30 ng/mL 
are required to avoid manifestation of vitamin D deficiency in the 
organs outside the skeletal system (2).
Vitamin D mediates its effects on autoimmune disorders by 
triggering immune responses through its receptors on macro-
phages, dendritic cells, and T and B lymphocytes. Thus, the re-
lationship between vitamin D deficiency and autoimmune thy-
roid disorders may also be related with vitamin D receptor (VDR) 
gene polymorphisms as well as environmental factors. Recently, 
Graves disease (GD) has been associated with vitamin D deficien-
cy (3-6). Serum 25(OH)D levels were shown to be significantly 
lower and inversely correlated with thyroid volume in patients 
with new-onset GD compared to control subjects (7). Vitamin D 
deficiency was also reported to be associated with lower remis-
sion rates in GD (8, 9). In this study, we aimed to investigate the 
impact of baseline vitamin D levels on thyroid volume in patients 
with new-onset GD.
METHODS
Study Group
The patients who were admitted to the endocrinology and me-
tabolism outpatient clinic with a diagnosis of new-onset GD 
were included in the study (n=61, F: 40, M: 21). The serum vitamin 
D levels were measured using the competitive protein- binding 
assay. The vitamin D status was defined as deficient, inadequate, 
and sufficient for vitamin D levels of <20 ng/mL, 20-30 ng/mL, 
and >30 ng/mL, respectively (1). According to the baseline se-
rum vitamin D status at the time of diagnosis, the patients were 
divided into three groups: vitamin D deficient group (Group-1; 
n: 42, F/M: 31/11), vitamin D inadequate group (Group-2; n=10, 
F/M: 4/6), and vitamin D sufficient group (Group-3; n: 9, F/M: 5/4). 
The diagnosis of GD was based on the standard clinical criteria, 
thyroid function tests with autoantibody levels, and thyroid scin-
tigraphy imaging. The serum free triiodothyronine (fT3) and free 
thyroxine (fT4) levels were measured using a competitive en-
zyme immunoassay. Serum thyroid stimulating hormone (TSH), 
thyroid receptor autoantibodies (TRAb), thyroid peroxidase au-
toantibodies (TPOAb), and thyroglobulin antibody (TgAb) levels 
were measured using a two-site immunoenzymetric assay. Thy-
roid volume (mL) and isthmus measurements (mm) were com-
pared between each group. Thyroid volume was calculated with 
using the following standardizsed formula (10).
Thyroid Volume (mL)=0.479×[Right lobe depth × width × 
length(cm)]+0.479 × [Left lobe depth × width × length(cm)]
Thyroid ultrasonography imaging for the calculation of thyroid 
volumes (mL) and isthmus measurements (mm) were performed 
by the same physician using Logic 7, General Electric, Milwau-
kee, Wiskonsin. Patients with a history of thyroidectomy, renal 
disease, hepatic disease, or malignancy or those under medica-
tions that affect vitamin D status and having prior replacement 
of vitamin D in the last 6 months were excluded from the study. 
The patients younger than 18 years and older than 75 years were 
also not included in the study groups. 
This study was approved by the ethics committee of Kanuni 
Sultan Süleyman Training and Research Hospital on 17.06.2016 
(2016/16) and written informed consent was obtained from all 
patients. All procedures were performed in accordance with the 
Declaration of Helsinki.
Statistical Analysis
The distribution of variables was evaluated using the Kolmogor-
ov-Smirnov test and a histogram analysis. The mean±standard er-
ror of the mean (SEM) and frequency values are reported for each 
data. The three groups were compared using ANOVA, Kruskal-Wal-
lis, and Mann-Whitney U tests, with the post-hoc Bonferroni adjust-
ment as appropriate. for statistically significant results. Categorical 
variables were processed using the chi-square test. The Pearson 
and Spearman correlation analysis was performed for normally 
and non-normally distributed data, respectively. A statistical signif-
icance was accepted at a p value of <0.05. Statistical calculations 
were performed using the Statistical Package for Social Sciences 
22.0 software (SPSS IBM Corp.; Armonk, New York, USA).
RESULTS 
A total of 61 patients were included in the study (F: 40, M: 21). The 
serum TSH levels were below 0.005 µIU/mL, and the fT4 and fT3 
levels were above upper limit of normal (1.71 ng/dL, 4.4 pg/mL) in 
all the patients. The mean age and vitamin D levels of the patients 
were 34.8±1.2 years (18-61) and 13.8±1.3 (2.5-39), respectively, 
(mean±SEM [min-max]). The distribution of the clinical features 
according to vitamin D levels are shown in Table 1. Thyroid vol-
umes and isthmus measurements did not show significant differ-
ence according to the baseline serum vitamin D levels at the time 
of diagnosis (p=0.8 and p=0.1, respectively; Table 1).
The presence of Graves ophthalmopathy was similar between the 
three groups (p=0.7). Thyroid volume was higher in males and in 
patients with body mass index (BMI) >25 (p=0.001 and 0.04, re-
spectively). The thyroid volume did not show significant differ-
ence according to presence of Graves ophthalmopathy (Table 2).
There was a positive correlation between thyroid volume and 
serum fT4, fT3, TRAb, TPOAb, and TgAb levels (p=0.001, r=0.426; 
p=0.001, r=0.50; p=0.04, r=0.26; p=0.001, r=0.42; p=0.001 r=0.42; 
respectively; Table 3). There was an inverse correlation between 
serum vitamin D levels and thyroid volume, TRAb, fT3, and para-
thyroid hormone (PTH) levels (p=0.02, r=-0.31; p=0.005, r=-0.36; 
p=0.04, r=-0.26; p=0.02, r=-0.32; respectively; Table 4).
Low baseline vitamin D and high TgAb levels were significantly as-
sociated with higher thyroid volume in a logistic regression analy-
sis (p=0.03, odds ratio [OR]: 18.7, 95% confidence interval [CI]:1.34-
260.91; p=0.04, OR: 16.6, 95% CI: 1.07-255.64, respectively; Table 5).
DISCUSSION
The major effect of vitamin D is on the regulation of bone and 
mineral homeostasis; however, it has been recently shown that 
hypovitaminosis D is also associated with extraskeletal disorders, 
Table 1. Distribution of clinical features according to the 
vitamin D status
 Group-1 Group-2 
 (vit D <20  (vit D >20 
 ng/mL) ng/mL) p 
Age (mean±SEM) 36.2±1.5 35.1±2.0 0.05
BMI 23.7±0.7 22.5±3.1 0.3
fT4 4.4±0.3 4.3±0.7 0.9
fT3 15.2±1.3 13.7±2.3 0.6
TRAb 9.4±1.4 9.1±4.5 0.5
TPOAb  335.6±38.6 317.9±89.7 0.5
TgAb 573±170 606±434 0.6
vit D 7.9±4.6 26.6±3.5 0.001
Ca 9.5±0.6 9.7±0.14 0.3
P 3.7±0.1 4.1±0.2 0.2
PTH 52±2.2 35.1±4.1 0.05
Thyroid Volume (mL) 31.9±2.7 26.8±5.0 0.3
Isthmus (mm) 4.8±0.4 3.7±0.8 0.1
BMI: body mass index, fT4: free thyroxine; fT3: free triiodothyronine; 
TRAb: thyroid receptor antibody; TPOAb: thyroid-peroxidase antibody; 
TgAb: thyroglobulin antibody; vit D: vitamin D; Ca: calcium, P: phosphorus; 
PTH: parathyroid hormone; SEM: standard error mean
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such as hypertension, diabetes mellitus, malignancy, cardiovas-
cular and autoimmune thyroid diseases (1). Vitamin D regulates 
inflammatory cytokine production and inhibits the proliferation 
of proinflammatory cells through its receptors on lymphocytes 
and macrophages (11). The effects of vitamin D on monocytes 
and macrophages is in favor of activating the innate immune sys-
tem;, however, there is an inhibitory effect on the acquired im-
mune response (12). These effects represent the immunomod-
ulatory action, which results in an association between vitamin 
D deficiency and autoimmune disorders. Vitamin D inhibits the 
production of Th1 cells by suppressing the function of interleu-
kin (IL)-2, IL-12, and interferon (IFN)-γ and stimulating IL-4, there-
by shifting the polarization of T cells towards the Th2 phenotype 
(13). The decrease in this inhibitory effect on Th1 production is 
related to an increase in the autoimmune thyroid disorders with 
vitamin D deficiency (1).
The relationship between low vitamin D levels and GD has been 
previously reported (14, 15). GD is characterized by a loss of im-
Table 2. Relationship of  thyroid volume with categorical 
variables
  Thyroid Volume  
  (mean±SEM) p
Gender
 Female  25±2.8 0.001
 Male 40±2.7 
Ophthalmopathy
 Absent 28.7±2.5 0.1
 Present 35.8±4.3 
Age, years
 <40 31.1±2.8 0.8
 >40 30.2±3.4 
BMI 
 <25 28.3±2.5 0.04
 >25 39.4±5.2 
Chi-square; SEM: standard error mean; BMI: body mass index
Table 3. Correlation of thyroid volume and isthmus thickness 
with clinical features
                 Thyroid Volume                Isthmus Thickness
 p r p r
Age, years 0.7 0.04 0.6  0.07
BMI  0.2 0.15 0.04 0.27
fT4 0.001 0.45 0.001 0.52
fT3 0.001 0.50 0.001 0.55
TRAb 0.04 0.26 0.001 0.40
TPOAb 0.001 0.42 0.1 0.21
TgAb 0.001 0.42 0.8 -0.02
Vit D 0.02 -0.31 0.3 -0.12
Ca 0.1 0.21 0.6   0.06
PTH 0.3 0.13 0.9 -0.004
P 0.7 0.03 0.1 -0.21
Pearson, Spearman; BMI: body mass index; fT4: free thyroxine; fT3: free 
triiodothyronine; TRAb: thyroid receptor antibody; TPOAb: thyroid-peroxi-
dase antibody; TgAb: thyroglobulin antibody; vit D: vitamin D; Ca: calcium; 
P: phosphorus; PTH: parathyroid hormone
Table 4. Correlation of vit D levels with clinical features
                                       Vit D 
 p r
Age, years 0.1 -0.11
BMI 0.7 -0.04
fT4 0.2 -0.16
fT3 0.04 -0.26
TRAb 0.01 -0.33
TPOAb 0.1 -0.11
TgAb 0.1 -0.11
Thyroid volume 0.02 -0.31
Ca 0.1 0.21
PTH 0.02 -0.32
P 0.04 0.28
BMI: body mass index; fT4: free thyroxine; fT3: free triiodothyronine; 
TRAb: thyroid receptor antibody; TPOAb: thyroid-peroxidase antibody; 
TgAb: thyroglobulin antibody; vit D: vitamin D; Ca: calcium, P: phosphorus; 
PTH: parathyroid hormone
Table 5. Logistic regression analysis of risk factors 
asociatedassociated with thyroid volume 
  Thyroid volume
 p OR CI 95%
Vitamin D 0.03 18.7 1.34-260.91
Age, years 0.8 1.19 0.19-7.2
BMI 0.1 0.14 0.18-1.11
Gender 0.002 142.85 0.0-0.15
fT4 0.5 0.38 0.01-9.33
fT3 0.1 13.9 0.68-285,67
TRAb 0.4 0.30 0.02-4.25
TPOAb 0.4 0.47 0.07-3.04
TgAb 0.04 16.6 1.07-255.64
BMI: body mass index; fT4: free thyroxine; fT3: free triiodothyronine; 
TRAb: thyroid receptor antibody; TPOAb: thyroid-peroxidase antibody; 
TgAb: thyroglobulin antibody; vit D: vitamin D; PTH: parathyroid hormone; 
OD: odds ratio; CI: confidence interval
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mune tolerance to thyroid antigens leading to the inflammation 
of thyroid gland (3). Thus, the decreased inhibitory effect on the 
immune system caused by hypovitaminosis D is thought to act 
as a further reinforcement in the development of GD. Vitamin D 
levels were shown to be decreased and related with thyroid vol-
ume in patients with new-onset GD (7). Furthermore, lower levels 
of vitamin D were reported to be associated with lower rates of 
remission in patients with GD (8). To the best of our knowledge, 
this is the first study investigating the change in thyroid volumes 
according to the baseline serum vitamin D levels among patients 
with new-onset GD. In our study, the mean thyroid volume and 
isthmus measurements did not show significant difference be-
tween the three groups according to the vitamin D status. How-
ever, thyroid volumes had an inclination to be higher in patients 
with lower vitamin D levels revealing a negative correlation be-
tween the two parameters. In contrast, thyroid volumes showed 
positive correlation with thyroid hormones and autoantibody 
levels. Higher autoantibody levels causing enhanced stimulation 
of thyroxine synthesis, accompanied with a further increase in 
the volume of thyroid gland, is the possible explanation of this 
relation. 
In an animal in vivo autoimmune thyroiditis model, vitamin D 
treatment is shown to reduce the severity of inflammatory le-
sions in the thyroid gland (16). It is also reported that lower vi-
tamin D levels are associated with higher thyroid autoantibody 
levels (17, 18). In our study, there was an inverse correlation 
between baseline vitamin D levels and serum TRAb titers. This 
may be associated with the lack of an inhibitory action on the 
immune system due to decreased vitamin D levels. In our study, 
there was a tendency to higher fT3 levels in patients with low-
er levels of vitamin D, which may be related with the increased 
TRAb titers and further stimulation of the inflammatory changes 
in the thyroid gland.
In addition to vitamin D deficiency due to environmental factors, 
vitamin D receptor (VDR) polymorphism is also reported to be 
an important cofactor in the development of GD (19). In a recent 
meta-analysis, significant difference in the association of vitamin 
D levels and GD has been reported in African and Asian patients, 
while no significant difference was found in the European popu-
lation (20). These differences might be related with the VDR poly-
morphisms among different ethnic populations. The increased 
prevalence of autoimmune thyroid disorders according to VDR 
polymorphisms has been reported in several studies (19, 21). The 
most common polymorphisms are reported as Apal and Fokl 
polymorphisms in Hashimoto disease and Taql polymorphism 
in GD (22). In a study performed in the Turkish population, Taql 
and Fokl genotypes were shown to be associated with higher 
prevalence of Hashimoto thyroiditis (23). Despite the negative 
correlation of vitamin D and thyroid volumes, the lack of differ-
ence in the mean thyroid volumes between the three groups in 
our study may be due to the presence of these polymorphisms; 
however, further studies are needed to demonstrate the VDR 
genotypes related with GD in the Turkish population.
In our study, thyroid volume was higher in male patients accom-
panied with higher BMI values, which was also related with an 
increased gland size. There was no significant difference in the 
rates of ophthalmopathy development according to the vita-
min D levels, and the thyroid volumes were similar in patients 
with and without Graves ophthalmopathy. Previous studies have 
shown that there was no difference in the severity of GD accord-
ing to the vitamin D status (7, 24). However, higher fT3 and TRAb 
levels were observed with lower vitamin D levels in our study. 
Nevertheless, the ophthalmopathy presence was similar be-
tween the three groups. The higher fT3 and TRAb levels may also 
be the reason for lower remission rates of GD in vitamin D defi-
ciency, which has been previously reported (8).
The limitation to our study is that it was a single-center cross-sec-
tional study with a limited number of patients. Prospective larg-
er scale studies with vitamin D treatment and follow- up for the 
onset of remission are needed to make definitive suggestions. 
Studies of vitamin D receptor polymorphisms associated with 
GD among different population groups would also be beneficial 
for further conclusions.
CONCLUSION
Vitamin D deficiency is an important risk factor in the develop-
ment of autoimmune thyroid disorders. Baseline serum vitamin 
D levels are inversely related to fT3, TRAb levels, and thyroid vol-
umes, which are related to the adverse outcomes in GD. There-
fore, in addition to several advantages, optimization of vitamin 
D levels would also be beneficial on the surveillance of these 
patients. However, larger scale studies on different ethnic popu-
lations are required to make further suggestions.
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